Biolex Therapeutics Inc., of Pittsboro, N.C., said its Phase IIb trial of Locteron to treat hepatitis C virus showed that the percentage of patients who maintained undetectable levels of virus at week 60 were comparable or exceeded the response rate for the PEG-Intron control
NovaBay Pharmaceuticals Inc., of Emeryville, Calif., reported that clinical and bacteriological response rates of children with impetigo treated with three concentrations of the firm's Aganocide compound, NVC-422, ranged from 84 percent to 95 percent at end of treatment and at follow-up...The response rate for methicillin-resistant Staphylococcus aureus (MRSA) was 100 percent, whether the MRSA was the sole organism or in a mixed infection
The primary objective is objective response rate per RECIST 1.1, where response is defined as complete response, partial response and stable disease for 12 weeks or longer
An objective response rate was seen in 7 percent of patients in the overall study, 10 percent in patients who were EGFR wild-type, 4 percent in those with EGFR mutations and 12 percent for those with KRAS wild-type mutations
Biothera, of Eagan, Minn., reported that a combination of its Imprime PGG and Erbitux (cetuximab, Eli Lilly and Co.) doubled the overall response rates for second- and third-line metastatic colorectal cancer patients in a Phase Ib/IIa trial
Seattle Genetics Inc., of Bothell, Wash., said top-line data from a Phase II trial of single-agent brentuximab vedotin (SGN-35) in relapsed/refractory anaplastic large cell lymphoma showed an 86 percent objective response rate...Ltd.'s Millennium unit, also recently showed a 75 percent response rate in relapsed/refractory Hodgkin's lymphoma
The primary endpoint is overall response rate, with secondary endpoints evaluating durable response, disease control, progression-free survival and safety
The response rate to combination treatment reached 85 percent, based on prostate-specific antigen decline within three months...The primary endpoint of the study is objective response rate, with secondary endpoints of duration of response and overall survival
Clinical benefit was observed for 90 percent of patients, with only three progressors at six months, and objective response rate was 50 percent compared to the 25 percent reported in the historical control group
The primary endpoint is objective response rate over a six-month period, which was, at the interim analysis, 11 percent with a median duration of response of 6.9 months...Ten patients (67 percent response rate) demonstrated objective tumor responses, including several patients with complete tumor responses
The previously reported top-line results included a high complete pathological response rate and a low relapse rate in combination with cisplatin and radiation, combined with a relatively benign side effect profile
Clinical response rates at the end of treatment were 85 percent, 87 percent and 92 percent, respectively, for the low, median and high doses...Bacterial response rates were 87 percent, 89 percent and 95 percent for the ascending doses, and the response rate for the 10 patients infected with MRSA who completed treatment was 100 percent
Though primarily a safety study, data showed that the clinical response rate for Cubicin was numerically higher than the comparator at the test-of-cure visit one to two weeks following the second surgery to place a new prosthetic...The open-label study is expected to enroll up to 86 patients with nonsquamous disease, with a primary endpoint of overall response rate measured using RECIST criteria
The 22-patient second arm of the study showed a response rate of 24 percent for the Imprime PGG plus Erbitux group, with a stable disease rate of 38 percent and progression-free survival of 12 weeks...That compares to historical Erbitux-only data showing an 11 percent response rate, a 22 percent stable disease rate and PFS of six weeks
BLISS-76 data recently presented at the 2010 Congress of the European League Against Rheumatism showed that belimumab 10 mg/kg plus standard of care met the primary endpoint of the Phase III study by achieving a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care
Best overall response rate from the trial was 61 percent (28 of 46 patients) with 11 percent (five of 46) of the patients achieving a clinical complete response...Those results compared favorably to data from a separate published study showing an objective response rate of 41 percent with no complete responses in a similar patient population receiving docetaxel alone
The study will recruit up to 50 patients who have progressed on platinum-based therapy, with primary objectives of objective response rate and safety